Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
There's a heck of a D&D match going on right now between Intellia Therapeutics (representing Team Data) and Wall Street analysts and investors (Team Doubt). This contest really heated up in the past few days. Team Data came out swinging hard, with great results in NTLA's Phase 3 trial of a drug called Lonvo-z. But Team Doubt came back with a vengeance. Instead of rising, as one might have hoped, NTLA stock lost 14% on Friday 4/24/26 and dropped another 4% on Monday 4/27/26. I can envision Team Data making a comeback in the months ahead. But the ongoing tenacity of Team Doubt prevents me from raising my currently neutral “Hold” rating for Intellia stock. NoSystem images/E+ via Getty Images I wonder how many people (besides me) have never played Dungeons & Dragons, commonly known as D&D That famous role-playing game debuted in 1974. But back then, I was more interested in disco. During that year, Disco broke beyond its underground heritage
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a "market outperform" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..MarketBeat
- Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..MarketBeat
- Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 4/27/26 - Form 424B5
- 4/27/26 - Form 8-K
- 4/10/26 - Form 8-K
- NTLA's page on the SEC website